Results 11 to 20 of about 1,518 (207)

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History [PDF]

Dermatology and Therapy
Introduction For some patients with atopic dermatitis (AD), topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and systemic therapies are inadequate to control disease or are associated with adverse events (AEs).
Andrew Blauvelt, Howard Kallender, Daniel Sturm, Qian Li, Haobo Ren, Lawrence F. Eichenfield   +5 more
doaj   +4 more sources

Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database [PDF]

ClinicoEconomics and Outcomes Research
Jinan Liu,1 Karishma Desai,2 Chia-Chen Teng,2 Daniel Sturm,1 Grace Stockbower,2 Hiten Patadia,1 Vincent Willey2 1Incyte Corporation, Wilmington, DE, USA; 2Carelon Research, Inc., Wilmington, DE, USACorrespondence: Jinan Liu, Incyte Corporation, 1801 ...
Liu J, Desai K, Teng CC, Sturm D, Stockbower G, Patadia H, Willey V   +6 more
doaj   +5 more sources

Treatment of cutaneous lupus with topical ruxolitinib cream [PDF]

JAAD Case Reports, 2022
Jonathan J. Park, PhD, Alicia J. Little, MD, PhD, Matthew D. Vesely, MD, PhD   +2 more
doaj   +4 more sources

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study [PDF]

JAAD International
Hequn Huang, MM, Dawei Duan, MM, He Huang, MD, Xianfa Tang, MD, Caihong Zhu, MD, Yaohua Zhang, MD, Min Li, MD, Yujun Sheng, MD, Leihong Xiang, MD, PHD, Yong Cui, MD, Youwen Zhou, MD, Xuejun Zhang, MD, PHD, Bo Zhang, MD, PHD   +12 more
doaj   +3 more sources

Ruxolitinib cream for the treatment of granuloma annulare [PDF]

JAAD Case Reports
Austin J. Piontkowski, BS, Nancy Wei, MD, Aisha Mumtaz, MD, Nicholas Gulati, MD, PhD   +3 more
doaj   +4 more sources

Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. [PDF]

Drugs
Kang C.
europepmc   +4 more sources

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream [PDF]

JAAD Case Reports, 2022
Shannon Nugent, BS, Alexandra J. Coromilas, MD, Joseph C. English, III, MD, Misha Rosenbach, MD   +3 more
doaj   +4 more sources

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab [PDF]

JAAD Case Reports, 2023
Juna Khang, BA, J. Michael Yardman-Frank, MD, MPH, Li-Chi Chen, MD, MPH, Hye Jin Chung, MD, MMSc   +3 more
doaj   +4 more sources

Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream [PDF]

JAAD Case Reports
Sophia S. Tran, BS, Benjamin Ungar, MD, Patrick M. Brunner, MD, MSc   +2 more
doaj   +4 more sources

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream [PDF]

Journal of Allergy and Clinical Immunology, 2019
Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.We sought to evaluate the efficacy and safety of ruxolitinib (RUX) cream in adults with AD.In this phase 2 study (NCT03011892), 307 ...
Brian Kim, Michael Howell, Kang Sun, Kim Papp, Adnan Nasir, Michael E. Kuligowski   +5 more
openalex   +4 more sources